BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 15218357)

  • 1. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
    Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
    Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
    Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
    Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
    J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.
    Lüftner D; Henschke P; Flath B; Akrivakis C; Schnabel S; Prinz B; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2004; 24(2B):895-906. PubMed ID: 15161043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
    Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
    Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
    Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.